My watch list  

632 Newest Publications in expert review of neurotherapeutics


You can refine your search further. Select from the filter options on the left to narrow down your results.

Neuroprotective actions of thyroid hormones and low-T3 syndrome as a biomarker in acute cerebrovascular disorders

11-Feb-2015 | Adomas Bunevicius; Giorgio Iervasi; Robertas Bunevicius, Expert Review of Neurotherapeutics, 2015

Acute cerebrovascular disorders are common causes of death and disability worldwide. Prognostication of stroke victims rests mainly on admission clinical and radiological indexes of disease severity. Preclinical studies strongly suggest that thyroid hormones have a capacity to exert ...


The potential of induced pluripotent stem cells in models of neurological disorders: implications on future therapy

09-Feb-2015 | Jeremy Micah Crook; Gordon Wallace; Eva Tomaskovic-Crook, Expert Review of Neurotherapeutics, 2015

There is an urgent need for new and advanced approaches to modeling the pathological mechanisms of complex human neurological disorders. This is underscored by the decline in pharmaceutical research and development efficiency resulting in a relative decrease in new drug launches in the last ...


Progress in the treatment of small fiber peripheral neuropathy

09-Feb-2015 | Ming-Chang Chiang; Ming-Tsung Tseng; Chun-Liang Pan; Chi-Chao Chao; Sung-Tsang Hsieh, Expert Review of Neurotherapeutics, 2015

Small fiber neuropathy is a syndrome of diverse disease etiology because of multiple pathophysiologic mechanisms with major presentations of neuropathic pain and autonomic symptoms. Over the past decade, there has been substantial progress in the treatments for neuropathic pain, dysautonomia and ...


Further understanding of tau phosphorylation: implications for therapy

02-Jan-2015 | Miguel Medina; Jesús Avila, Expert Review of Neurotherapeutics, 2015

Tau is a brain microtubule-associated protein that regulates microtubule structure and function. Prominent tau neurofibrillary pathology is a common feature in a number of neurodegenerative disorders collectively referred to as tauopathies, the most common of which is Alzheimer’s disease. Beyond ...


Targeting the neurophysiology of cognitive systems with transcranial alternating current stimulation

30-Dec-2014 | Flavio Fröhlich; Kristin K Sellers; Asa L Cordle, Expert Review of Neurotherapeutics, 2014

Cognitive impairment represents one of the most debilitating and most difficult symptom to treat of many psychiatric illnesses. Human neurophysiology studies have suggested that specific pathologies of cortical network activity correlate with cognitive impairment. However, we lack demonstration ...


Charting a path toward combination therapy for Alzheimer’s disease

26-Dec-2014 | Diane Stephenson; Dan Perry; Cynthia Bens; Lisa J Bain; Donald Berry; Michael Krams; Reisa Sperling; David Dilts; Jo ..., Expert Review of Neurotherapeutics, 2014

It is acknowledged that progress in combined therapeutic approaches for Alzheimer’s disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer’s Disease Coalition and the Critical Path Institute, investigators from ...


Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future

24-Dec-2014 | Harald Hampel; Lon S Schneider; Ezio Giacobini; Miia Kivipelto; Shireen Sindi; Bruno Dubois; Karl Broich; Robert Nis ..., Expert Review of Neurotherapeutics, 2014

Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer’s disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. ...


Potential mechanisms and clinical applications of mild hypothermia and electroconvulsive therapy on refractory status epilepticus

15-Dec-2014 | Xiaoyan Yang; Xuefeng Wang, Expert Review of Neurotherapeutics, 2014

Status epilepticus (SE) is an acute and severe neurological disorder. A small number of SE cases cannot be terminated by a sufficient therapeutic dose and duration of two to three common anticonvulsant therapies. The continuing seizures often lead to poor prognosis and a higher mortality rate. ...


Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

15-Dec-2014 | William James Deardorff; Ahmad Shobassy; George T Grossberg, Expert Review of Neurotherapeutics, 2014

Alzheimer’s disease (AD) is a prevalent and currently incurable brain disease whose impact will continue to rise as the population ages. With limited treatment options, a variety of experimental therapies are currently in clinical trials. EVP-6124 (encenicline) is an α7 nicotinic acetylcholine ...


Pharmacological approaches for Alzheimer’s disease: neurotransmitter as drug targets

12-Dec-2014 | Atish Prakash; Jaspreet Kalra; Vasudevan Mani; Kalavathy Ramasamy; Abu Bakar Abdul Majeed, Expert Review of Neurotherapeutics, 2014

Alzheimer’s disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in ...


Page 1 From 64
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE